Moderna stock (NASDAQ: MRNA) just delivered one of the most dramatic single-day moves in biotech history. Shares skyrocketed roughly 177% on Wednesday, August 19, after Moderna and partner Merck announced that their personalized mRNA cancer vaccine — combined with Merck's blockbuster immunotherapy Keytruda — met its primary goal in a late-stage Phase 3 trial designed to keep melanoma from returning. The news re-rated the stock overnight and left investors racing to determine whether the rally still has room to run.

Inside Moderna's Historic 177% Surge

The announcement was the long-awaited payoff for Moderna's biggest pipeline bet beyond COVID-19. The company said the Phase 3 trial of its individualized neoantigen therapy, known as mRNA-4157 (V940), given together with Keytruda (pembrolizumab), met the trial's primary endpoint of preventing recurrence in patients with high-risk melanoma following surgery. Reuters framed the result as a "breakthrough" that "could usher in a wave of cancer vaccines," opening a new avenue of treatment that doctors hope will work against many types of tumors, not just melanoma.

Moderna mRNA cancer vaccine trial news
Moderna stock skyrocketed on the personalized mRNA cancer vaccine trial news. Image credit: Fast Company - Source

The market's response was immediate and historic. Moderna shares jumped nearly 177% on Wednesday — the biggest one-day gain in the company's history — while Merck also climbed. Just as quickly, the momentum cooled. On Thursday, August 20, Moderna tumbled more than 10% in pre-market trading as investors locked in profits from the surge. By Friday, August 21, the buyers were back: the stock climbed another 16.57% to roughly $155, pushing Moderna's market capitalization to about $62 billion.

Timeline: From Falling COVID Sales to a Cancer Vaccine Breakthrough

Moderna's path to this moment was anything but smooth. After peaking during the pandemic, the company's COVID-19 vaccine business steadily shrank, dragging trailing-twelve-month revenue down 27.6% to about $2.23 billion and leaving the company with a net loss of roughly $3.15 billion.

The cancer vaccine program emerged as the centerpiece of Moderna's post-COVID strategy. The therapy, co-developed with Merck, repurposes the same mRNA platform that powered Moderna's COVID shot to teach a patient's immune system to recognize and attack the specific mutations found in their own tumor.

The key milestones that led to this week's surge:

  • 2023–2025: Moderna and Merck advance mRNA-4157/V940 into late-stage testing for melanoma after earlier-phase data suggested a meaningful reduction in the risk of recurrence when added to Keytruda.
  • August 19, 2026: The companies announce the Phase 3 trial met its primary goal of preventing melanoma recurrence. Moderna surges roughly 177%, its largest one-day gain ever.
  • August 20, 2026: Shares pull back more than 10% in pre-market trading as traders take profits.
  • August 21, 2026: The stock rallies again, rising 16.57% to about $155 as Wall Street's re-ratings sink in.

Why Wall Street Raced to Re-Rate Moderna Stock

The data prompted a rapid-fire repricing of analyst targets, even as the broader consensus rating stayed at "Hold." Among the most notable moves:

  • UBS analyst Michael Yee nearly tripled his price target to $150 from $50.
  • Bank of America Securities upgraded the stock and raised its target to $170 from $40.
  • Goldman Sachs lifted its target to $120 from $67.
  • Morgan Stanley raised its target to $89 from $39.
Analysts debate the Moderna cancer vaccine opportunity
Analysts debated how much of the cancer-vaccine opportunity is already priced in. Image credit: The Wall Street Journal - Source

The gap between the stock's price and the average analyst target tells its own story. According to data compiled by S&P Global from 23 analysts, the consensus one-year price target sits near $89 — roughly 42% below where Moderna was trading on Friday. Targets range from a low of $25 to a high of $170, reflecting deep disagreement about how much of the cancer-vaccine opportunity is already priced in.

The stakes are substantial. The melanoma indication alone represents a meaningful market, but Reuters reported that doctors and analysts see the approach extending across many tumor types. If the personalized mRNA platform proves broadly applicable, Moderna's $2.23 billion in trailing revenue and ongoing losses could look very different a few years from now. The stock's roughly 467% jump in market value over the past year shows just how aggressively investors are pricing in that possibility.

Where Moderna Stock Stands Now

Moderna traded near the $155 level on Friday morning, up about 16.6% on the day, with a market value close to $62 billion. The move has lifted the stock far above where it traded before the announcement, but it remains just below the highest Wall Street target of $170.

The company's financial picture still shows a business in transition. Trailing revenue of roughly $2.23 billion is down sharply from the pandemic peak, and the company is not yet profitable, posting a net loss of about $3.15 billion over the trailing twelve months. Analysts currently project revenue of about $2.11 billion for fiscal 2026 and $2.43 billion for 2027 — modest growth that does not yet fully capture a potential cancer-vaccine launch.

What Happens Next for Moderna and Merck

The next steps are likely to center on regulatory filings and the full presentation of the Phase 3 data. Investors will watch for the detailed recurrence-free survival results, the safety profile, and the companies' plans to seek regulatory approval and expand into additional tumor types.

The biggest question hanging over the stock is valuation. After a nearly 177% single-day move followed by a renewed rally, much of the near-term enthusiasm may already be reflected in the price — a dynamic underscored by an average analyst target well below the current level. For investors, the tension is between a transformative pipeline story and a stock that has already repriced dramatically. The wide range of price targets, from $25 to $170, reflects genuine uncertainty about how large the cancer-vaccine market will ultimately be.

The Bottom Line: Key Takeaways for Investors

  • Moderna and Merck's personalized mRNA cancer vaccine met its primary Phase 3 goal in melanoma, preventing recurrence when combined with Keytruda.
  • Moderna stock surged roughly 177% on August 19, its biggest one-day gain ever, and continued climbing to about $155 by August 21.
  • Wall Street rapidly raised price targets — UBS to $150, BofA to $170, Goldman to $120 — but the consensus rating remains a Hold with an average target near $89.
  • Moderna is still unprofitable, with revenue down 27.6% and a $3.15 billion trailing net loss, making the cancer vaccine the key swing factor for the stock.